Versantis launches first clinical study

Versantis will now be testing its drug therapy VS-01 on patients. A Phase 1b study has been initiated at the hospital of the Goethe University Frankfurt. This means that after animal testing, the safety, efficacy and tolerability of the Versantis drug is being investigated on healthy humans for the first time. Recently founded as a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH), Versantis has developed a method for quickly and efficiently clearing ammonia and other toxins from the body. This enables the treatment of both chronic and acute liver diseases. 

Versantis was established four years ago. The biotech startup reported that the begin of clinical trials “marks a new era” for Versantis. Testing of its multi-organ support therapy is expected to be completed by spring 2020. It will then be followed by Phase 2 trials.